Surufatinib: First Approval-Reference-Cited by-同舟云学术

Surufatinib: First Approval

Published:2021-03-31 Issue:6 Volume:81 Page:727-732
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Syed Yahiya Y.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-021-01489-y.pdf

Reference26 articles.

1. Xu JM, Wang Y, Chen YL, et al. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget. 2017;8(26):42076–86.

2. HUTCHMED. Our pipeline. 2020. https://www.hutch-med.com. Accessed 4 Feb 2021.

3. Lyons YA, Pradeep S, Wu SY, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017;8(57):96496–505.

4. Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38(1):3–15.

5. HUTCHMED. Chi-Med announces the NMPA approval of surufatinib (Sulanda® in china) for non-pancreatic neuroendocrine tumors [media release]. 2020. https://www.hutch-med.com. Accessed 30 Dec 2020.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models;Frontiers in Pharmacology;2024-04-05

2. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential VEGFR-2 inhibitors, apoptotic inducers;Bioorganic Chemistry;2024-04

3. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R;Communications Chemistry;2024-01-03

4. Antineoplastic indole-containing compounds with potential VEGFR inhibitory properties;RSC Advances;2024

5. Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer;Journal of Advanced Research;2024-01